FDA Approves First Targeted Oral Therapy, Lisraya, for Dermatomyositis

The U.S. Food and Drug Administration (FDA) has granted approval to Lisraya (brepocitinib), developed by Roivant Sciences and Priovant Therapeutics, as the first targeted oral treatment for adults with dermatomyositis (DM). This milestone represents a significant advancement for the rare autoimmune disease, moving beyond broad immunosuppression to a therapy that specifically targets underlying disease mechanisms by inhibiting TYK2 and JAK1 pathways.